SBRT plus QL1706 for advanced liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of a special type of radiation (SBRT) and an immunotherapy drug (QL1706) as a second option for people with advanced liver cancer that hasn't been controlled by initial treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 75 years old.
- Your liver cancer must have spread or gotten worse after you've already tried one type of cancer medicine.
- You should be in generally good health (able to do daily activities with little help).
- Liver function must be well enough (Child-Pugh score A or B7).
- You must have 3 or fewer tumors in your liver, and they cannot have spread to other organs.
- You must be willing to use birth control if you could become pregnant or get someone pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called QL1706 for people with advanced liver cancer that has worsened after a previous immunotherapy treatment. The goal is to see if it can help slow down the cancer.
This trial tests a combination of immunotherapy and high-precision radiation (SBRT) to shrink large or multiple liver tumors in people with hepatocellular carcinoma, with the goal of making them small enough for surgery. It's for people who cannot currently have their tumors removed but might become eligible after treatment.
This trial tests a combination of radiation therapy with two drugs (QL1706 and bevacizumab) for people with liver cancer that hasn't spread to other parts of the body but can't be surgically removed. The goal is to see if this approach can shrink or control the tumor.
This trial tests whether a targeted radiation therapy (SBRT) can help people with liver cancer whose disease has only a few new spots growing while on first-line immunotherapy. It aims to see if zapping those spots can control the cancer and delay the need for stronger treatments.
This trial tests whether adding targeted radiation therapy (SBRT) to standard systemic therapy helps people with advanced liver cancer live longer compared to systemic therapy alone.
This trial tests a new drug called QL1706 combined with standard chemotherapy and radiation to shrink liver tumors in patients with colon cancer that has spread to the liver. The goal is to make these tumors small enough to remove surgically.
Hear when a new HCC - Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.